Cardiac biointerventions: Whatever happened to stem cell and gene therapy?

Todd K. Rosengart, Eleanor Fallon, Ronald Crystal

Research output: Contribution to journalReview article

9 Citations (Scopus)


Angiogenic gene therapy and stem cell administration represent two "biologic" interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these "biointerventions" may be expected in the near future.

Original languageEnglish
Pages (from-to)173-179
Number of pages7
JournalInnovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Issue number3
Publication statusPublished - 1 May 2012
Externally publishedYes



  • Angiogenesis
  • Gene therapy
  • Heart failure
  • Stem cells
  • VEGF

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this